Advertisement Fluoroalkyl ethers for Drug Design - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More


Fluoroalkyl ethers for Drug Design

More than 20% of all modern pharmaceuticals and up to 30% of agrochemicals contain at least one fluorine atom. As a typical fluoroalkoxy group, trifluoromethoxy (-OCF3) is prevalent in bioactive compounds. Compared to the well-studied -OCF3 group, its bulkier analogue, pentafluoroethoxy (-OC2F5) group, has been much less explored. In fact, -OC2F5 and -OCF3 groups have similar electronic properties, lipophilicity and metabolic stability.

In this context, Enamine offers a library of various fluoroalkyl-substituted ethers for drug design.

We offer more than 50 of fluoroalkyl ethers from stock on a 5-10 g scale.

For design and a full list, you can find at MedChem Highlights section of Enamine’s
website or in the white paper attachment.